Russia's sovereign wealth fund said on Friday it had signed a deal with South Korea's GL Rapha for the biotechnology firm to produce over 150 million doses per year of the Sputnik V coronavirus vaccine. However, the vaccines made by GL Rapha will be for export only, not distributed in Korea, as the nation has yet to approve the vaccine for local use.
The Russian "Sputnik V" vaccine for Covid-19 has arrived in India following the nod to Pharma major Dr Reddy's Laboratories to conduct an adaptive phase 2/3 human clinical trial for the vaccine in the country. The college principal also said Sputnik V's effect on the volunteers will be evaluated for seven months after the vaccine is administered once, twice or thrice within an interval of 21 days.
However, it has also reached agreements to produce 500 million doses annually overseas, which will supply other countries.
Production will begin in December and the vaccine will be exported to countries around the world starting in January 2021. RDIF is now considering additional requests from a number of countries and companies to further increase its foreign production capacities.
Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population.
Last week, Pfizer said its experimental COVID-19 vaccine was over 90% effective based on initial trial results.
The vaccine's developers looked at 94 infections recorded so far in a study that has enrolled almost 44,000 people in the USA and five other countries.
Such skepticism started as early as in August when the Russian health authorities approved it without going through the final phase 3 trial. This calculation was based on 20 confirmed cases of COVID-19 among the 40,000 people who participated in the clinical trial.
Sputnik V still lacks these things, he added.